What are the recommended dosing regimens for nifedipine (immediate‑release and extended‑release) for hypertension and angina, including dose adjustments for elderly patients, renal impairment, and hepatic impairment?

Nifedipine Dosing Recommendations

For hypertension, start nifedipine extended-release at 30 mg once daily on an empty stomach, titrate over 7-14 days to a usual maintenance dose of 30-60 mg once daily (maximum 90 mg daily), and avoid immediate-release nifedipine capsules entirely as they are no longer recommended due to safety concerns. 1, 2

Extended-Release Formulations (Preferred)

Hypertension Dosing

• Initial dose: 30 mg once daily on an empty stomach 1
• Titration: Increase over 7-14 days based on therapeutic response and tolerability 1
• Usual maintenance: 30-60 mg once daily 1
• Maximum dose: 90 mg once daily (titration above 90 mg not recommended) 1
• Administration: Swallow tablets whole; do not bite or divide 1

The FDA label emphasizes that extended-release tablets provide 24-hour therapeutic coverage with once-daily dosing, with trough/peak ratios of 41-78% for diastolic and 46-91% for systolic blood pressure 1. Clinical trials demonstrated dose-related blood pressure reductions across the 30-90 mg range 1.

Angina Dosing

For angina pectoris, the same extended-release dosing applies (30-90 mg once daily) 3. However, immediate-release nifedipine should never be used for angina without concurrent beta-blocker therapy due to increased risk of adverse cardiovascular events 3.

Immediate-Release Formulations (Generally Avoided)

Critical safety warning: Immediate-release nifedipine capsules should no longer be prescribed for routine hypertension or angina management 2. The 1999 British Hypertension Society guidelines explicitly state that "nifedipine in capsule form should no longer be prescribed" 2.

The only potential exception is hypertensive emergencies in intensive care settings, where immediate-release nifedipine has shown a per-patient adverse event incidence of 7.3%, though this remains controversial 4. For hypertensive emergencies, intravenous nicardipine (5-15 mg/h) or clevidipine (1-32 mg/h) are strongly preferred over any oral nifedipine formulation 5, 6.

Special Population Adjustments

Elderly Patients (≥60 years)

• No dose adjustment required for extended-release formulations 5
• Elderly patients show 36% higher Cmax and 70% greater average plasma concentrations, but this does not necessitate dose reduction 1
• Extended-release nifedipine 20 mg twice daily was effective and well-tolerated in elderly hypertensives (mean age 73 years) without orthostatic hypotension 7
• Dihydropyridine calcium channel blockers like nifedipine are compelling indications for elderly patients with isolated systolic hypertension 8

Renal Impairment

• No specific dose adjustment recommended, but use with caution 1
• Pharmacokinetic studies show oral clearance of 1189 ml/min and half-life of 6 hours remain relatively stable across degrees of renal failure 9
• Doses of 20-40 mg twice daily achieved normotension in 8 of 9 patients with renal failure without deterioration in creatinine clearance 9
• The pyridine metabolite is not retained in renal failure 9
• Monitor closely as absorption from extended-release tablets could be modified by renal disease 1

Hepatic Impairment

• Use with significant caution and expect need for dose reduction 1
• Patients with liver cirrhosis demonstrate longer elimination half-life and higher bioavailability than healthy volunteers 1
• Protein binding (normally 92-98%) is greatly reduced in hepatic impairment, increasing free drug levels 1
• Start at lower end of dosing range and titrate slowly with close monitoring

Administration Timing Considerations

Research suggests bedtime administration may be superior to morning dosing for both efficacy and tolerability 10:

• Bedtime dosing of 60 mg nifedipine GITS showed twice the efficacy of morning dosing in non-responders to 30 mg
• Bedtime administration reduced edema incidence by 91% and total adverse events by 74% compared to morning dosing (p=0.026) 10
• Both timing regimens provide full 24-hour coverage with 30 mg daily 10

Critical Drug Interactions and Contraindications

Avoid grapefruit juice entirely - causes up to 2-fold increase in AUC and Cmax due to CYP3A4 inhibition 1. Nifedipine is extensively metabolized via CYP3A4, so any strong CYP3A4 inhibitors or inducers will significantly alter drug levels 1.

Contraindications for dihydropyridine calcium channel blockers: None are absolute for nifedipine specifically, though caution is warranted in advanced aortic stenosis 5.

Discontinuation Protocol

Taper gradually under close physician supervision when discontinuing nifedipine extended-release 1. Abrupt cessation should be avoided to prevent rebound hypertension or angina.

Common Pitfalls to Avoid

1. Never prescribe immediate-release nifedipine capsules for routine outpatient management 2
2. Never use immediate-release nifedipine for angina without concurrent beta-blocker 3
3. Do not crush, chew, or divide extended-release tablets - this destroys the controlled-release mechanism 1
4. Do not substitute three 30 mg tablets for one 90 mg tablet - this produces substantially higher Cmax values 1
5. Avoid combining with rate-limiting calcium channel blockers (verapamil, diltiazem) or in heart failure without specialist guidance 8
6. Monitor for peripheral edema, particularly with morning dosing and higher doses 10